Mehmet Haluk Yücel

11PUBLICATIONS
47CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Nutrigenomics and personalised nutritionModels of care and place of birthMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Sep 25, 2026
Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer.

|Sep 08, 2026
Clinicopathologic Features of NRG1 Fusion-Positive Non-Small Cell Lung Cancer.

|May 04, 2026
Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy.

|May 04, 2026
A Novel Biological Index for Predicting Neoadjuvant Treatment Response in HER2-Positive Breast Cancer: The Tumor-Immune-Proliferation-Inflammation (TIPI) Score.

|May 04, 2026
Survival Outcomes After irAE-Related Nivolumab Discontinuation in mNSCLC: A Multicenter Study.

|Mar 28, 2026
Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study.

Maral Martin Mildanoglu, Mehmet Haluk Yucel, Ebru Engin Delipoyraz

Pageof 2

Frequent Collaborators

7 joint publications

Harun Muğlu

7 joint publications

Ahmet Bilici

6 joint publications

Jamshid Hamdard

6 joint publications

Özgür Açıkgöz